PhaseBio rises on positive data from blood clotting drug trial

PhaseBio Pharmaceuticals

04/04/2022 14:57

** Drug developer's shares  PHAS.O  rise ~2.5% to $1.24
    ** Co's experimental drug, bentracimab, meets main goal of
reversing anti-clotting effect of AstraZeneca Plc's  AZN.L 
blood thinner Brilinta in mid-stage study  urn:newsml:reuters.com:*:nFWN2W20PV
    ** Trial enrolled 205 older volunteers between ages of 50
and 80 years, with 154 subjects receiving bentracimab and 51
subjects receiving placebo 
    ** All participants were pre-treated with dual antiplatelet
therapy composed of Brilinta and low-dose aspirin
    ** Co remains on track to submit marketing application with
U.S. FDA in mid-2022
    ** The drug is currently Being tested in a late-stage trial
    ** Stock down ~52% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))